Alzheimer's Disease (AD) is a degenerative brain disorder that results in memory loss, dementia, and ultimately death. This disease affects over 27 million people worldwide, and will affect 1 in 85 people by 2050; to date, there is no cure for this disease. The path towards finding a cure for any disease often starts with identifying molecular "targets" at which new drugs can be aimed. There are relatively few AD targets and so new targets must be sought and new drugs developed. We have discovered a novel target, called CXCR2, and have validated its potential in AD therapeutics. In this proposal, we detail our systematic approach towards developing and evaluating new therapeutic compounds that act on CXCR2 in order to treat AD.